Inventiva annonce que son partenaire Sino Biopharm a reçu l'approbation de sa demande d’IND par la NMPA pour démarrer le développement clinique de lanifibranor en Chine
25 mai 2023 16h00 HE
|
INVENTIVA
Chia Tai Tianqing Pharmaceutical Group Co., Ltd., filiale de Sino Biopharm, a reçu l'approbation de sa demande d’IND par la NMPA permettant l’initiation du développement clinique en Chine...
Inventiva announces that its partner Sino Biopharm received IND approval from the NMPA to initiate clinical trial with lanifibranor in China
25 mai 2023 16h00 HE
|
INVENTIVA
Chia Tai Tianqing Pharmaceutical Group Co., Ltd., a Sino Biopharm’s subsidiary, receives IND approval from the NMPA to initiate the clinical development in mainland China of lanifibranor in NASHSino...
Nonalcoholic Steatohepatitis Clinical Trial Pipeline Analysis of 100+ Companies | NASH Pipeline Report by DelveInsight
23 mai 2023 13h00 HE
|
DelveInsight Business Research LLP
New York, USA, May 23, 2023 (GLOBE NEWSWIRE) -- Nonalcoholic Steatohepatitis Clinical Trial Pipeline Analysis of 100+ Companies | NASH Pipeline Report by DelveInsight Nonalcoholic steatohepatitis...
Inventiva publie ses informations financières du 1er trimestre 2023¹ et fait un point sur ses activités
16 mai 2023 16h00 HE
|
INVENTIVA
Au 31 mars 2023, trésorerie et équivalents de trésorerie à 56,3 millions d’euros, dépôt court terme à 0,7 million d’euros2 et dépôt long terme à 9,3 millions d'euros3, contre 86,7 millions d’euros,...
Inventiva reports 2023 First Quarter Financial Information¹ and provides a corporate update
16 mai 2023 16h00 HE
|
INVENTIVA
Cash and cash equivalents at €56.3 million, short-term deposits at €0.7 million2, and long term deposit at €9.3 million3 as of March 31, 2023, compared to €86.7 million, €1.0 million and €0.7 million...
Madrigal Pharmaceuticals to Participate in the JMP Securities Life Sciences Conference
11 mai 2023 08h00 HE
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., May 11, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic...
Madrigal Pharmaceuticals Provides Corporate Updates and Reports First Quarter 2023 Financial Results
09 mai 2023 08h00 HE
|
Madrigal Pharmaceuticals, Inc.
Resmetirom new drug application (NDA) filing on track for Q2 2023Resmetirom has received Breakthrough Therapy designation from FDA Multiple resmetirom abstracts accepted for presentation at EASL,...
ICER MIDWEST CEPAC WORKS TO KEEP UP WITH WELL-INFORMED NASH PATIENT ADVOCATES
01 mai 2023 17h36 HE
|
Global Liver Institute
Washington, DC, May 01, 2023 (GLOBE NEWSWIRE) -- On Friday, the Institute for Clinical and Economic Review (ICER) held a public hearing to review its draft assessment of Resmetirom and Obeticholic...
PATIENT GROUPS DECLARE ICER REVIEW OF NASH MEDICATIONS CAUSES MORE UNCERTAINTY AND CONTROVERSIES THAN IT RESOLVES
28 avr. 2023 12h22 HE
|
Global Liver Institute
Washington, DC, April 28, 2023 (GLOBE NEWSWIRE) -- Today, the Institute for Clinical and Economic Review (ICER) will hold a public hearing on its draft assessment of Resmetirom and Obeticholic Acid...
Madrigal Receives Breakthrough Therapy Designation from FDA for Resmetirom and Completes Enrollment of the Phase 3 MAESTRO-NASH Biopsy Trial
18 avr. 2023 08h00 HE
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., April 18, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic...